# Merck (MRK) — News MRK · NYSE · Stock Canonical page: https://www.lighthorse.io/tickers/mrk/news ## Recent headlines - [Merck & Co Inc: RBC cuts target price to $145 from $150](https://www.ainvest.com/news/merck-rbc-cuts-target-price-145-150-2610) — AInvest Wire, Oct 12, 2026 RBC Capital has adjusted its price target for Merck & Co Inc (MRK), lowering it to $145 from a previous target of $150. The revised forecast reflects updated expectations regarding the company’s performance and market conditions. While the change is relatively modest, it signals a cautious outlook… - [Merck & Co - Remigromig demonstrates non-inferior visual acuity versus ranibizumab at one year in DME](https://www.ainvest.com/news/merck-remigromig-demonstrates-inferior-visual-acuity-ranibizumab-year-dme-2610) — AInvest Wire, Oct 10, 2026 Merck & Co. has reported topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating its investigational tetravalent, tri-specific antibody Remigromig (MK-3000) in patients with diabetic macular edema (DME). At 52 weeks, both tested doses of Remigromig (0.5 mg and 0.8 mg) demonstrated… - [Vaxcyte closes $1.15B offerings of stock, warrants, notes](https://www.ainvest.com/news/vaxcyte-closes-1-15b-offerings-stock-warrants-notes-2610) — AInvest Wire, Oct 9, 2026 Vaxcyte, Inc. (Nasdaq: PCVX) has completed a $1.15 billion capital-raising initiative, comprising $500 million in common stock and pre-funded warrants and $500 million in convertible senior notes due 2032, with an additional $150 million in over-allotment options exercised by underwriters. The… - [Bio-pharmaceutical stocks fell in intraday trading, with Eli Lilly down 4.73%, Amgen falling 2.93% and Merck sliding 2.33%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-intraday-trading-eli-lilly-4-73-amgen-falling-2-93-merck-sliding-2-33-2610-74) — AInvest Wire, Oct 8, 2026 Bio-pharmaceutical stocks experienced a decline in intraday trading on Monday, with several major players posting notable losses. Eli Lilly shares dropped 4.73%, while Amgen fell 2.93%. Merck also saw a decline, with its stock sliding 2.33% . The downward movement reflects broader market volatility… - [Perspective Thera gets designation for PSV359](https://www.ainvest.com/news/perspective-thera-designation-psv359-2610) — AInvest Wire, Oct 8, 2026 Perspective Therapeutics has announced a clinical collaboration with Merck to evaluate its targeted alpha therapy, [212Pb]PSV359, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of FAP-α-positive solid tumors. The collaboration involves amending… ## Similar Stocks - [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock - [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock - [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock - [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock - [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock - [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock - [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock - [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock - [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares - [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).